Establishment and characterization of a novel cell line, NCC-MFS1-C1, derived from a patient with myxofibrosarcoma

Kito, Fusako; Oyama, Rieko; Sakumoto, Marimu; Shiozawa, Kumiko; Qiao, Zhiwei; Toki, Shunichi; Yoshida, Akihiko; Kawai, Akira; Kondo, Tadashi

doi:10.1007/s13577-018-00233-1

Cited by 11 publications

(16 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We examined the antitumor effects of 210 drugs on NCC-MFS5-C1 cells. The cell viability of NCC-MFS5-C1 cells after drug treatment is summarized in Table S5 , along with the cell viabilities of NCC-MFS1-C1 [ 28 ], NCC-MFS2-C1 [ 29 ], NCC-MFS3-C1 [ 30 ], and NCC-MFS4-C1 [ 31 ] cells, which we previously reported. The drugs were categorized into three groups according to their antitumor effect: cluster A, effective group; cluster B, intermediate effect group; cluster C, poor effect group ( Figure 4 a).…”

Section: Resultsmentioning

confidence: 99%

“…The IC 50 values of NCC-MFS5-C1 were calculated for the drugs that were hit in the screening study, and are summarized in Table S6 , along with those of NCC-MFS1-C1 [ 28 ], NCC-MFS2-C1 [ 29 ], NCC-MFS3-C1 [ 30 ], and NCC-MFS4-C1 [ 31 ]. Notably, the proteasome inhibitor, bortezomib, and the histone deacetylase (HDAC) inhibitor, romidepsin, showed a more remarkable antitumor effect in all five MFS cell lines than doxorubicin, which is used as a standard drug for the treatment of sarcomas ( Figure 5 , Table 3 ).…”

Section: Resultsmentioning

confidence: 99%

“…Invasive potential was assessed using a real-time cell analyzer (xCELLigence, Agilent, Santa Clara, CA, USA) along with NCC-MFS1-C1 [ 28 ], NCC-MFS2-C1 [ 29 ], NCC-MFS3-C1 [ 30 ], and NCC-MFS4-C1 [ 31 ], as previously reported [ 32 ]. We seeded cells (4 × 10 4 ) suspended in a serum-free DMEM/F12 medium in the upper chamber coated with BD Matrigel matrix (BD Biosciences, Franklin Lakes, NJ, USA) ( n = 2).…”

Section: Methodsmentioning

confidence: 99%

“…Cell viability was calculated by comparing with the DMSO control. The acquired data were analyzed using the results of NCC-MFS1-C1 [ 28 ], NCC-MFS2-C1 [ 29 ], NCC-MFS3-C1 [ 30 ], and NCC-MFS4-C1 [ 31 ], which we previously reported. Quantile normalization was performed using R (version 4.0.3, limma package version 3.46.0, Bioconductor), and unsupervised hierarchical clustering was performed using the gplots package (version 3.1.0, CRAN, , accessed on 28 October 2021).…”

Section: Methodsmentioning

confidence: 99%

“…Thus, we established an MFS cell line and named it NCC-MFS5-C1 using surgical specimens of MFS. In addition to a detailed characterization of the cell line, we attempted to identify novel candidate drugs by integrating the results of drug screening studies for the following MFS cell lines, as reported in our previous studies: NCC-MFS1-C1 [ 28 ], NCC-MFS2-C1 [ 29 ], NCC-MFS3-C1 [ 30 ], and NCC-MFS4-C1 [ 31 ].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Establishment and Characterization of NCC-MFS5-C1: A Novel Patient-Derived Cell Line of Myxofibrosarcoma

Tsuchiya

Yoshimatsu²,

Noguchi³

et al. 2022

Cells

Self Cite

View full text Add to dashboard Cite

Myxofibrosarcoma (MFS) is a highly aggressive malignancy with complex karyotypes and a postoperative recurrence tendency, owing to its strong invasiveness. Although systemic chemotherapy is considered in patients with unresectable MFS, the efficacy of conventional chemotherapy is hitherto unclear. Recently, drug screening analysis using a large number of tumor cell lines has been attempted to discover novel therapeutic candidate drugs for common cancers. However, the number of MFS cell lines is extremely small because of its low incidence—this hinders the conduction of screening studies and slows down the development of therapeutic drugs. To overcome this problem, we established a novel MFS cell line, NCC-MFS5-C1, which was shown to harbor typical MFS genetic abnormalities and thus had useful properties for in vitro studies. We conducted the largest integrated screening analysis of 210 drugs using NCC-MFS5-C1 cells along with four MFS cell lines, which we previously reported. Bortezomib (a proteasome inhibitor) and romidepsin (a histone deacetylase inhibitor) showed stronger antitumor effects than the standard drug, doxorubicin. Therefore, the NCC-MFS5-C1 cell line can potentially contribute to elucidating MFS pathogenesis and developing a novel MFS treatment.

show abstract